Zobrazeno 1 - 10
of 15
pro vyhledávání: '"Jithesh J. Augustine"'
Autor:
Bingbing Dai, Jithesh J. Augustine, Ya’an Kang, David Roife, Xinqun Li, Jenying Deng, Lin Tan, Leona A. Rusling, John N. Weinstein, Philip L. Lorenzi, Michael P. Kim, Jason B. Fleming
Publikováno v:
Cell Death and Disease, Vol 12, Iss 7, Pp 1-11 (2021)
Abstract Nuclear factor erythroid 2-related factor 2 (NRF2) is aberrantly activated in about 93% of pancreatic cancers. Activated NRF2 regulates multiple downstream molecules involved in cancer cell metabolic reprogramming, translational control, and
Externí odkaz:
https://doaj.org/article/16cff39c74954feaa55f9afe71d7a3b7
Autor:
Mayrim V. Rios Perez, David Roife, Bingbing Dai, Michael Pratt, Ryszard Dobrowolski, Ya'an Kang, Xinqun Li, Jithesh J. Augustine, Rafal Zielinski, Waldemar Priebe, Jason B. Fleming
Publikováno v:
Surgery Open Science, Vol 1, Iss 2, Pp 56-63 (2019)
Background: Auranofin, a Food and Drug Administration–approved anti-rheumatic agent with anticancer properties for lung and ovarian cancer, has never been studied for pancreatic cancer. We hypothesize that auranofin may prevent pancreatic ductal ad
Externí odkaz:
https://doaj.org/article/8c733fed64cf494fa7abb5b45dd29bc7
Autor:
Guillermina Lozano, Jason B. Fleming, Amanda R. Wasylishen, Michelle C. Barton, Bin Liu, Anirban Maitra, Timothy P. Heffernan, Christopher A. Bristow, Florencia McAllister, Eugene J. Koay, Shunbin Xiong, Joy M. McDaniel, Ya'an Kang, Jithesh J. Augustine, Christian Siangco, Tara G. Hughes, Kendra L. Allton, Bingbing Dai, Yun Zhang, Jenying Deng, Xinqun Li, Michael P. Kim
Supplementary Figure 3
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7660d885033ed528f78e469605aeae8c
https://doi.org/10.1158/2159-8290.22539451
https://doi.org/10.1158/2159-8290.22539451
Autor:
Guillermina Lozano, Jason B. Fleming, Amanda R. Wasylishen, Michelle C. Barton, Bin Liu, Anirban Maitra, Timothy P. Heffernan, Christopher A. Bristow, Florencia McAllister, Eugene J. Koay, Shunbin Xiong, Joy M. McDaniel, Ya'an Kang, Jithesh J. Augustine, Christian Siangco, Tara G. Hughes, Kendra L. Allton, Bingbing Dai, Yun Zhang, Jenying Deng, Xinqun Li, Michael P. Kim
Mutant p53-associated genes
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::69eec2c83bf1dfcb224158947f03f18e
https://doi.org/10.1158/2159-8290.22539442.v1
https://doi.org/10.1158/2159-8290.22539442.v1
Autor:
Bingbing Dai, Bin Liu, Christian Siangco, Jason B. Fleming, Tara Hughes, Timothy P. Heffernan, Christopher A. Bristow, Michelle Craig Barton, Jithesh J. Augustine, Anirban Maitra, Kendra Allton, Ya'an Kang, Guillermina Lozano, Michael P. Kim, Yun Zhang, Eugene J. Koay, Xinqun Li, Florencia McAllister, Shunbin Xiong, Joy M. McDaniel, Amanda R. Wasylishen, Jenying Deng
Publikováno v:
Cancer Discovery. 11:2094-2111
Pancreatic ductal adenocarcinoma (PDAC) is almost uniformly fatal and characterized by early metastasis. Oncogenic KRAS mutations prevail in 95% of PDAC tumors and co-occur with genetic alterations in the TP53 tumor suppressor in nearly 70% of patien
Autor:
Ryszard Dobrowolski, Bingbing Dai, Jason B. Fleming, Xinqun Li, Waldemar Priebe, Jithesh J. Augustine, Mayrim V. Rios Perez, Ya'an Kang, David Roife, Rafal Zielinski, Michael Pratt
Publikováno v:
Surgery Open Science, Vol 1, Iss 2, Pp 56-63 (2019)
Surgery Open Science
Surgery Open Science
Background Auranofin, a Food and Drug Administration–approved anti-rheumatic agent with anticancer properties for lung and ovarian cancer, has never been studied for pancreatic cancer. We hypothesize that auranofin may prevent pancreatic ductal ade
Autor:
Michael P, Kim, Xinqun, Li, Jenying, Deng, Yun, Zhang, Bingbing, Dai, Kendra L, Allton, Tara G, Hughes, Christian, Siangco, Jithesh J, Augustine, Ya'an, Kang, Joy M, McDaniel, Shunbin, Xiong, Eugene J, Koay, Florencia, McAllister, Christopher A, Bristow, Timothy P, Heffernan, Anirban, Maitra, Bin, Liu, Michelle C, Barton, Amanda R, Wasylishen, Jason B, Fleming, Guillermina, Lozano
Publikováno v:
Cancer Discov
Pancreatic ductal adenocarcinoma (PDAC) is almost uniformly fatal and characterized by early metastasis. Oncogenic KRAS mutations prevail in 95% of PDAC tumors and co-occur with genetic alterations in the TP53 tumor suppressor in nearly 70% of patien
Abstract 2417: Mutant p53 and oncogenic KRAS converge on CREB1 to drive pancreatic cancer metastasis
Autor:
Joy M. McDaniel, Florencia McAllister, Guillermina Lozano, Michael Paul Kim, Jason B. Fleming, Yun Zhang, Christopher A. Bristow, Ya'an Kang, Anirban Maitra, Jenying Deng, Tara Hughes, Bin Liu, Kendra Allton, Bingbing Dai, Xinqun Li, Jithesh J. Augustine, Timothy P. Heffernan, Michelle Craig Barton, Amanda Wasylischen, Christian Siangco, Eugene J. Koay, Shunbin Xiong
Publikováno v:
Cancer Research. 81:2417-2417
Pancreatic ductal adenocarcinoma (PDAC) is almost uniformly fatal and characterized by early metastasis. Oncogenic KRAS mutations prevail in 95% of PDAC tumors and co-occur with genetic alterations in the TP53 tumor suppressor in nearly 70% of patien
Publikováno v:
Cancer Research. 79:4786-4786
Background: Signal Transduction and Activator of Transcription-3 (STAT3), though typically inactive in normal cells, is aberrantly active in cancer cells. Activation of STAT3 has been found in many types of cancers, including non-small cell lung canc
Autor:
Jessica A. Sorrentino, Patrick J. Roberts, Ya'an Kang, Jason B. Fleming, Michael P. Kim, Bingbing Dai, Daniel M. Freed, Jithesh J. Augustine, Tara Hughes
Publikováno v:
Cancer Research. 79:4732-4732
Introduction: In pancreatic ductal adenocarcinoma (PDAC), mutations in KRAS and deletion or promoter methylation of the CDKN2A gene - resulting in deregulation of the p16/CDK4/CDK6/RB axis - each occur in over 90% of cases. Therefore, combination the